{"groups":[{"description":"Participants received pembrolizumab 200 mg, intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).","id":"FG000","title":"Pembrolizumab"},{"description":"Participants received Investigator's choice of paclitaxel 80-100 mg/m\\^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m\\^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m\\^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).","id":"FG001","title":"Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"29"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"270"},{"groupId":"FG001","numSubjects":"262"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"19"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"4"}],"type":"Sponsor's decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"314"},{"groupId":"FG001","numSubjects":"314"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"314"},{"groupId":"FG001","numSubjects":"296"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}],"type":"Received Second Course of Pembrolizumab"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"314"},{"groupId":"FG001","numSubjects":"314"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"At the time of the primary analysis data cut-off of 15-Oct-2018, 67 participants were ongoing in the study."}